European Commission approves Lonsurf in combination with bevacizumab for the third-line treatment of metastatic colorectal cancer – Servier + Taiho
Taiho Pharmaceutical announced that its partner Servier, has won European regulatory approval for Lonsurf (trifluridine + tipiracil) in combination with bevacizumab for the third-line treatment of metastatic colorectal… read more.
